- Corient Private Wealth LP purchased a new position of 187,447 shares in Halozyme Therapeutics, Inc. valued at approximately $14,671,000 during the second quarter.
- Institutional investors and hedge funds currently own 97.79% of the biopharmaceutical company's stock, alongside recent insider share sales by executives.
- Halozyme Therapeutics reported second-quarter earnings with $2.28 EPS and $481.00 million in revenue, while maintaining a market capitalization of $11.96 billion.
